UBS Maintains Buy on Revolution Medicines, Raises Price Target to $265

Benzinga Newsdesk www.benzinga.com Positive 83.8%

Neg 0% Neu 0% Pos 83.8%

UBS analyst Michael Yee maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $220 to $265.